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Abstract
Background: Lactose intolerance is a form of lactose maldigestion where individuals experience symptoms such as
diarrhea, abdominal cramping, flatulence, vomiting and bowel sounds following lactose consumption. Lactobacillus
acidophilus is a species of bacteria known for its sugar fermenting properties. Preclinical studies have found that
Lactobacillus acidophilus supplementation may assist in breaking down lactose; however, no human clinical trials
exist evaluating its efficacy in alleviating symptoms related to lactose intolerance.
Objective: The aim of this randomized, double-blind, placebo-controlled, crossover study was to evaluate the effect
of a proprietary strain of Lactobacillus acidophilus on relieving discomfort related to lactose intolerance.
Methods: The study enrolled healthy volunteers between 18 and 75 years of age who complained of lactose
intolerance. Screening visits included a lactose challenge visit to confirm eligibility based on a score of 10 or higher on
subjective assessment of the following symptoms after lactose challenge: diarrhea, abdominal cramping, vomiting,
audible bowel sounds, flatulence, and overall symptoms. Qualified subjects participated in a 2-arm crossover design,
with each arm consisting of 4 weeks of intervention of either active or placebo product, with a 2-week washout period
during crossover. The study product consisted of the DDS-1 strain of Lactobacillus acidophilus (Nebraska Cultures,
Walnut Creek, California). The placebo was formulated from maltodextrin. Study participants were instructed to take the
product once daily for 4 weeks. Data collected included subjective symptom scores related to lactose intolerance.
Results: Longitudinal comparison between the DDS-1 group and placebo group demonstrated statistically significant
reductions in abdominal symptom scores during the 6-h Lactose Challenge at week 4 for diarrhea (p = 0.033), abdominal
cramping (p = 0.012), vomiting (p = 0.0002), and overall symptom score (p = 0.037). No adverse events were reported.
Conclusions: The present study has found that this unique DDS-1 strain of Lactobacillus acidophilus, manufactured by
Nebraska Cultures, is safe to consume and improves abdominal symptom scores compared to placebo with respect to
diarrhea, cramping, and vomiting during an acute lactose challenge.
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Introduction
Lactose maldigestion is a common condition affecting
up to 75 % of the world's population [1]. It results from
a normal physiologic decline in the activity of the brush-
border enzyme lactase, or beta-d-galactosidase [1, 2].
The lactase enzyme is responsible for cleavage of lactose,
a disaccharide carbohydrate consisting of glucose and
galactose and commonly found in mammalian milk [3].
When the amount of ingested lactose exceeds the hydro-
lytic capacity of lactase in the intestine, undigested lac-
tose is transported to the large intestine where it is
fermented by the bacterial microflora, producing organic
acids, carbon dioxide, and hydrogen. These byproducts,
along with the large amount of water osmotically drawn
into the intestine, lead to the commonly known symp-
toms of abdominal pain, bloating, cramps, and flatulence
[4, 5]. Audible bowel sounds have also been described as
a common complaint among lactose maldigesters [6–8].
Lactase expression reaches its peak at birth in preparation
for breastfeeding and begins to wean from that point until
it reaches undetectable levels [3]. Gastrointestinal path-
ology such as infection, inflammatory bowel disease, and
abdominal surgery can hasten this process [5].
It is important to distinguish lactase deficiency from
lactose malabsorption and lactose intolerance. Lactase
deficiency involves the natural physiologic reduction in
brush-border lactase activity that initiates after birth [5].
Lactose malabsorption is the process whereby lactose is
not absorbed in the intestine. Lactose intolerance is de-
fined as the clinical syndrome of hypolactasia and lactase
maldigestion resulting from the physiologic process of
lactose maldigestion [9]. The extent to which undigested
lactose causes the lactose intolerance symptoms depends
on a number of factors, including amount of lactose
ingested, small-intestinal lactase activity, gastric empty-
ing rate, transit time, and gastrointestinal microflora
composition [3, 10]. Lactose maldigesters can consume
0.5–7 g of lactose, which is equivalent to approximately
3 oz of milk, without experiencing symptoms of intoler-
ance [11]. Lactose maldigestion, therefore, does not ne-
cessarily lead to lactose intolerance.
While the gold standard for diagnosis of lactase defi-
ciency is through gastrointestinal mucosal biopsy, lactose
maldigestion in humans is often assessed using the
hydrogen breath test (HBT) [12, 13]. The HBT measures
the concentration of exhaled hydrogen after consump-
tion of lactose, specifically defined as > 20 ppm in one
breath after consumption of 50 g lactose. The increase
in exhaled hydrogen results from the release of
hydrogen-containing methane byproducts during bacter-
ial ingestion of lactose [14]. Lactose intolerance, the
clinical manifestation of lactose malabsorption, is a
subjective phenomenon commonly assessed using self-
reported symptom assessment scales [14].
Conventional management of lactose intolerance pri-
marily involves curtailment of dairy product consump-
tion [15, 16]. However, as dairy products provide an
excellent source of calcium, potassium, vitamin D, B vi-
tamins and high quality protein, avoidance of these
foods may increase the risk for bone fracture, osteopor-
osis and other adverse health effects [17, 18]. Another
commonly used treatment option involves supplementa-
tion with the lactase enzyme [19, 20]. Recent trends aim
to alter the natural intestinal flora to create an environ-
ment more conducive to lactose breakdown and absorp-
tion through the use of probiotic supplements [15, 21].
Alteration of colonic bacteria is thought to increase the
intra-intestinal lactase activity and thus reduce the ef-
fects of fermentation products [22, 23]. A number of
studies have demonstrated that cultured yogurt possess
considerable enzyme activity primarily due to the lactase
produced by lactic acid bacteria (LAB) such as Lactoba-
cillus acidophilus and Lactobacillus bulgaricus [24–27].
This is beneficial to individuals suffering from lactose in-
tolerance because of reduced lactose and lactase pro-
duced [4]. Numerous research studies have also shown
that LAB encourages the growth of proteolic enzymes
and lipases involved in the breakdown of protein, fat, and
carbohydrates [28–31]. L. acidophilus has also been shown
to carry antimicrobial properties [32–36] as well as anti-
carcinogenic and immunological properties [37–42].
The DDS-1 strain of Lactobacillus acidophilus, discov-
ered in 1959 by Dr. Khem Shahani at the University of
Nebraska, is a unique strain of L. acidophilus on deposit
with the FDA Agricultural Research Service (ARS) with
the catalog number B-3208. It is currently manufactured
by Nebraska Cultures, Inc. A recent study demonstrated
the DDS-1 strain of L. acidophilus to be superior to
other strains of lactobacillus in the ability to establish
in the human gastrointestinal (GI) tract [43]. This
present study evaluates the effect of L. acidophilus




The investigational product for this study was the DDS-
1 strain of Lactobacillus acidophilus (Nebraska Cultures,
Inc., Walnut Creek, California). The placebo was dis-
pensed in an identical capsule formulated from malto-
dextrin. The sponsor provided both the DDS-1 study
product and placebo product. Blinding was ensured with
the use of identical bottles, outer packaging, labeling and
color for the investigation products. Study participants
were instructed to take one capsule with food once daily
(every morning) for 4 weeks. The capsules with DDS-1
L. acidophilus contained not less than 10 billion (1 X
1010) CFU per dose. As the product and placebo are not
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classified as pharmaceutical drugs and the study does
not aim to satisfy claims to diagnose, treat, or prevent a
disease process, it does not fall under the category of in-
vestigational drug. Thus, Food and Drug Administration
review is not required for execution of this clinical trial.
Study participants
Study subjects were recruited via online advertising and
were phone screened prior to scheduling an in-clinic
screening visit. Inclusion criteria included age between
18 and 75 years, body mass index (BMI) of between 18
and 35 kg/m2, score of 10 or higher on 6-h symptom
score following lactose challenge, and agreement to stop
consumption of probiotic products or lactose digestion
aids two weeks prior to the study. Females of child bear-
ing potential agreed to use appropriate birth control
methods during the entire study period. Subjects with
congenital lactose deficiency, any significant GI condi-
tion including ulcerative colitis, Crohn’s disease, or
diarrhea as well as any clinically significant medical
conditions (e.g., surgery within the past six months,
history of seizure) were excluded from the study. The
full list of inclusion and exclusion criteria are detailed
in Table 1.
The lactose challenge was used to determine eligibility
during screening; subjects were included if they had a
symptom score of 10 or more during an in-clinic lactose
challenge test where lactose was dissolved in water and
consumed. Lactose at 25 g per dose, which is equivalent
to 480 ml of milk, was used in this study instead of the
usual 50 g per dose for the lactose HBT [44] because it
more closely reflects the average amount of milk con-
sumed by the population [7].
Study Design
This study was a randomized, double-blind, placebo-
controlled, crossover clinical trial. Group allocation was
placed in individually numbered envelopes to maintain
blinding of all individuals. The subjects, as well as the
clinical staff, data management staff, and statistical
analysis staff were unaware of which study group each
participant was assigned. Medicus Research was the
contract research organization (CRO) for this study.
Institutional review board (IRB) approval was received
on January 24, 2013 by the IntegReview Ethical Review
Board (Austin, TX) prior to the initiation of any study-
related activities.
A statistical power calculation was performed on data
from the Ojetti et al. study [20]. Using the Wilcoxon
Mann-Whitney test, with a power of 0.80 and an
alpha of 0.05, the required sample size per group was
20. Therefore, a decision was made to aim to include
Table 1 Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
• Healthy volunteers≥ 30 and≤ 75 years of age.
• Body mass index (BMI) ≥ 18 and≤ 35 kg/m2.
• Lactose Challenge Test 6-hour Symptom Score (SSC) >10
• Judged by the Investigator to be in good health.
• Females of child bearing potential must agree to use appropriate
birth control methods during the entire study period.
• Agree not to initiate any new exercise or diet programs during
the entire study period.
• Agree to halt consumption of probiotic products or lactose
digestion aids two weeks prior to study.
• Agree not to change their current diet or exercise program
during the entire study period.
• Understands the study procedures and signs forms providing
informed consent to participate in the study and authorization
for release of relevant protected health information to the
study investigator.
• Subjects with congenital lactose deficiency.
• Any significant GI condition that would potentially interfere with
the evaluation of the study product including but not limited to:
o Inflammatory bowel disease (Ulcerative Colitis or Crohn’s Disease)
o Frequent diarrhea
o Surgery for weight loss (e.g., gastric bypass or lap band)
o History of gastrointestinal perforation.
o History of gastroparesis.
• Recent (within two weeks of Visit 1) episode of acute gastrointestinal
illness such as nausea, vomiting, or diarrhea.
• Consumption of antibiotics and/or laxatives within the three months prior
to the study
• History of immunocompromise or auto-immune disorder.
• Use of any immunosuppressive drugs in the last 12 months (including
steroids or biologics)
• Active infection requiring antibiotics, anti-viral medication, or
hospitalization
• Subjects with known sensitivities to the ingredients in the study
product
• Subjects who are pregnant or lactating
• Subjects with a history of seizure
• Subjects on anticoagulation therapy
• Subjects with known alcohol abuse or recreational drug abuse
• Subjects with brain and/or spinal cord injury
• Untreated or unstable hypothyroidism
• Subjects with any cancer in the last 5 years (except non-melanoma
skin cancer)
• Surgery within the last 6 months
• Any clinically significant burn within the last 6 months
• Abnormal physical examination
• Subjects unable to understand or follow the study protocol
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at least 30 subjects in a crossover fashion (30 per
group) to ensure that the study was adequately
powered.
The study duration was twelve weeks with a total of 8
visits for each subject. The initial screening visit (visit 1)
was performed two weeks prior to the baseline visit.
During screening, study participants underwent a de-
tailed and thorough informed consent process. Study
procedures only commenced after the study participant
agreed that he/she understood all details of the consent
documentation and the specific details of the study as
outlined in the consent document. After the consent
was signed, study-related procedures were performed,
including review of all inclusion and exclusion criteria.
The screening process also included a detailed medical
history, review of prior and concomitant medications,
physical examination, vital signs, anthropometric mea-
sures, and urine pregnancy testing. Subjects were dis-
pensed standardized foods, which were to be consumed
within 48-h prior to the next visit, and were instructed
to complete a gut health diary and GI symptom ques-
tionnaire. Subjects returned to the clinic for visit 1.5
having fasted for 10-h and having only consumed the
standardized foods, ensuring controlled intake of sugar,
carbohydrate, fiber, and dairy products for 48-h prior to
the visit. The purpose of labeling the visit 1.5 is because
the subjects were still in the screening phase of the study
and in order to conform with common standards of clin-
ical trials, the randomization visit is considered "visit 2."
The reason that visit 1.5 procedures cannot be per-
formed during screening is that the subject needs to be
provided with the standardized foods and must sign the
informed consent document prior to being asked to fast
for 10-h. During visit 1.5, subjects underwent the lac-
tose challenge test, where they ingested 25 g of lac-
tose dissolved in water. Subjects were administered a
validated 6-h symptom score (SSC) questionnaire
consisting of six abdominal-related items: diarrhea,
abdominal cramping, vomiting, audible bowel sounds,
flatulence, and overall symptoms hourly for 6-h. Sub-
jects also performed the HBT 10-min prior to lactose
consumption and at Time = 60-min, 120-min, and
180-min. Prior to leaving the clinic, they were
dispensed standardized foods, diaries and a stool kit
to collect their stool in the morning of visit 2.
Subjects who met all of the study inclusion criteria
and none of the exclusion criteria were assigned a
randomization number at visit 2. Subjects were ran-
domized into one of two groups based on an atmos-
pheric method for randomization. One group was
assigned the active product for visits 2, 3, and 4,
followed by placebo for visits 5, 6, and 7. The other
group was assigned placebo for visits 2, 3, and 4,
followed by the active product for visits 5, 6, and 7.
Study subjects and researchers were blinded as to
which product contains the active product or placebo.
After a two-week washout period of any dietary sup-
plements and lactose-containing products, subjects ar-
rived in the clinic for their baseline visit (visit 2), where
they were interviewed by the clinical staff to determine
changes in their medical history and whether they
started any new medications. Subjects also returned
their completed diaries and used stool kits at this visit.
Subjects who qualified were assigned a randomization
number and performed the Lactose Challenge Test
(HBT and 6-h SSC). A two-week supply of the study
product along with standardized foods and stool kit were
dispensed by the end of the visit. Subjects returned to
the clinic at visit 3 (week 2) and visit 4 (week 4) for re-
peat assessments. After a two-week washout period,
crossover of products was performed. Crossover of study
product was performed at visit 5, where subjects who
had received placebo at visit 2 would receive product at
visit 5, and those who received product at visit 2 would
receive placebo at visit 5. Otherwise, pre-visit prepar-
ation and visit procedures for visits 5, 6, and 7 were con-
ducted in a manner identical to visits 2, 3, and 4. An
outline of this visit breakdown is demonstrated in
Table 2. The breakdown of HBT and symptom score
measurement is outlined in Table 3.
Endpoints
The purpose of this study was to determine the efficacy of
the DDS-1 study product on providing symptomatic relief
for lactose intolerance. The primary objective was to com-
pare the effect of the study product to placebo on relieving
lactose intolerance symptoms through changes in 6-h
Symptom Scores from baseline following lactose challenge.
Symptoms include diarrhea, abdominal cramping, vomit-
ing, bowel sounds, flatulence, and overall symptoms. Sever-
ity of symptoms was evaluated using an 11-point scale
from 0 (no symptoms) to 10 (most severe symptoms).
The secondary objective was to compare the effect of
the DDS-1 study product to placebo on improving lactose
digestion assessed by hydrogen breath test. Stool form was
assessed using the Bristol Stool Scale. Daily GI question-
naires were also administered and included assessments of
bowel urgency, abdominal bloating, abdominal discom-
fort, satisfaction with bowel habits, flatulence, burping,
early satiety, nausea, vomiting, and borborygmi. The other
objectives were to assess the levels of bacterial cultures in
the stool and the effect of the study product on quality of
life as measured by a quality of life questionnaire.
Statistics
Parallel dual data entries were performed across all end-
points, followed by data validation and reconciliation of
parallel entry. The monitoring team compared the values
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on the original CRFs or source documents, correcting any
discrepancies found. All data elements were screened for
reasonableness, and all missing, suspicious, or impossible
values were referred back to the monitoring team for
query generation and resolution. The database was for-
mally locked after all flagged entries in the database were
resolved. The locked database was free of any changes on
the data sources and data entries. After closure of the
study, the product assignments were then distinguished
from the blinding codes and merged into a database for
unblinding the data. The product assignments were
then distinguished from the randomization or blinding
codes and merged into the database and data tables.
A modified per protocol (Mod PP) analysis was per-
formed to assess the efficacy variables of the study. Sub-
jects with at least one post-dose visit completed were
included in the analysis. Differences within time periods
for each arm (within group test) and differences between
two arms for each time point (between group tests) were
analyzed for each endpoint. Descriptive measures such
as means, standard deviations, and standard errors of
means were processed for each numeric endpoint on all
visits. Percentage changes were used to quantify increase
or decrease of endpoints from baseline for each arm.
Categorical endpoints were presented as frequency
tables, with corresponding percentages. For each endpoint
in ordinal scale, the differences in the medians within time
periods for each arm were tested for nominal significance
using non-parametric test (Wilcoxon Signed Rank Test or
Sign Test). For each endpoint in the interval/ratio scale
that followed semblance to normality, the difference from
baseline to each subsequent time point was tested for each
arm for nominal significance using the paired t-test. If the
data was found to violate assumptions on normality, the
non-parametric Wilcoxon Signed Ranks test or Sign
Test was used. For continuous endpoints at each time
point, the difference between means of different arms
was assessed for significance using either the paired
Student's t-test for endpoints satisfying parametric
assumptions or the non-parametric Wilcoxon Signed
Ranks test or Sign Test. For categorical endpoints, the
Sign Test was used to compare the difference between
arms for each time point.
All efficacy endpoints were analyzed depending on the
level of measurement of the endpoint. The 6-h symptom
score was analyzed using paired Student's t-test or by
the non-parametric Wilcoxon Signed Ranks test or Sign
Test for those data that were found to be substantially
non-normally distributed. Significant changes in occur-
rence of bowel movements of related samples were
observed weekly. In order to provide a longitudinal com-
parison for changes in symptoms between the active and
Table 3 6-Hour symptom score and Hydrogen breath testing
Pre-Lactose (−10 min) 1 hours 2 hours 3 hours 4 hours 5 hours 6 hours
6-Hour symptom score X X X X X X X
Hydrogen breath testing X X X X

















Week (−2) Week 0 Week 2 Week 4 Week 0 Week 2 Week 4
Informed consent process x
Inclusion/Exclusion x
Medical history & physical exam x
Vital signs x x x x x x x x
Urine pregnancy test x
Standardized meals x x x x x x x
Administer & review scales and
questionnaires
x x x x x x
Review concomitant therapies x x x x x x x
Intercurrent medical issues
review
x x x x x x x
Randomization/study product
preparation & dispensing
x x x x
Hydrogen breath test x x x x x x x
Fecal collection x x x x x x
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placebo groups, a linear mixed model analysis was also
performed.
Outcomes from the HBT were evaluated using the
univariate general linear model. Since the study was a
crossover study, three factors were considered: (1) the
product applied before the endpoint was measured, (2)
the order in which the product was applied, and (3) the
randomization group.
To obtain comparable documentation on adverse
events (AE), the investigator asked the subject the open,
standardized, questions at each visit. Frequency and
intensity of adverse events, including assessment of
seriousness, were recorded in detail during each visit.
Differences in AE patterns between product groups were
assessed by McNemar Change Test.
Results
Of the 126 individuals screened, 38 were randomized to
receive the study product or placebo, of which 18 were
initially placed in the product group and 20 in the pla-
cebo group. Fifteen subjects (7 in the active group and 9
in the placebo group) terminated the study early due to
relocation, loss to follow-up, or voluntary subject with-
drawal. Of these early termination subjects, one subject
completed the active portion and two subjects
completed the placebo portion of the study. No subject
withdrawals were related to adverse events. A total of 22
subjects completed both crossover arms of the study and
were included in the final analysis set, including 11 sub-
jects initially assigned to the active group on visit 2 and
11 subjects initially assigned the placebo group on visit
2. For within-group analysis, the total sample sizes were
23 for the active group and 24 for the placebo group. Of
note, one subject that completed only the active portion
of the study provided reliable data only for the flatulence
measure. Thus the total size of the active group was 22
for all measures except for flatulence, which was 23. A
graphical representation of the attrition data is presented
in Fig. 1.
Within-group analysis of the placebo group demon-
strated that after four weeks, a statistically significant in-
crease in symptoms of abdominal cramping (1.04 at
hour 0 to 2.33 at hour 6, p = 0.004) and overall symptom
score (4.79 at hour 0 to 9.71 at hour 6, p = 0.017) was
noted (Table 4). During this period, the product group
also demonstrated significant increases in overall symp-
tom score (3.86 at hour 0 to 8.23 at hour 6, p = 0.027),
as well as significantly increased flatulence (1.30 at hour
0 to 3.26 at hour 6, p = 0.027) (Table 5).
Using the linear mixed model, longitudinal comparison
between the DDS-1 and placebo group demonstrated a
statistically significant difference at week 4 in the diarrhea
symptom score (p = 0.033; 1.34 in the active group com-
pared to 1.69 in the placebo group), as well as abdominal
cramping (p = 0.012; 1.94 compared to 2.39 in the placebo
group), vomiting (p = 0.002; 0.08 compared to 0.36 in the
placebo group), and overall (p = 0.037; 9.28 compared to
10.51 in the placebo group) (Table 6).
The 6-h symptom scores for Bowel Sounds and
Flatulence were not statistically significantly different
between the DDS-1 and placebo group at any time
point during the course of the study. Furthermore, no
statistically significant differences between groups
were observed for the HBT, stool form as docu-
mented on Bristol Stool Scale, and the SF-12 quality
of life survey by the end of the study. Although stool
samples were collected, analysis of the stool was not
completed due to budgetary limitations as well as
positive findings based on 6-h symptom scores.
Discussion
In the present study, the effect of the DDS-1 study prod-
uct on relieving lactose intolerance symptoms was com-
pared to placebo. This study aimed to include subjects
reporting symptoms of lactose intolerance including
diarrhea, abdominal cramping, vomiting, audible bowel
sounds, and flatulence. Longitudinal evaluation found
the group receiving the placebo to have worsened symp-
toms on lactose challenge at 4 weeks compared with the
group receiving the DDS-1 strain of Lactobacillus acid-
ophilus. Of note, data on HBT, stool form, and the SF-12
quality of life survey did not yield statistically significant
results. Thus, for the purpose of brevity, these results
were not reported.
Use of probiotics in management of lactose maldiges-
tion stems from both anecdotal and empirical evidence
related to cultured yogurt consumption. Cultured yogurt
has been shown to possess considerable enzyme activity
primarily due to the lactase produced by probiotic bac-
teria such as Lactobacillus acidophilus, Lactobacillus
bulgaricus and Streptococcus thermophilus [24–27]. A
clinical study on 10 lactase non-persistent individuals,
ingestion of 18 g of lactose in yogurt resulted in signifi-
cantly lower hydrogen excretion compared to ingestion
of milk with an equal amount of lactose, implying a bet-
ter absorption of lactose in yogurt. Fewer reports of diar-
rhea or flatulence were also observed in subjects who
consumed yogurt [26]. The bacterial lactase is thought to
be superior to synthetic lactase enzyme due to the ability to
withstand the acidity of the stomach through encasement
within the bacterial cells. As the yogurt enters the small in-
testine, the slower gastrointestinal transit time permits the
activation of lactase, digesting lactose efficiently. Bile is then
thought to emulsify the bacterial cell walls, resulting in re-
lease of lactase in the intestinal tract [27, 45]. Thus the en-
zyme activity in yogurt depends upon the buffer capacity of
the microbial cells in yogurt to resist stomach acid as well
as the effect of bile on the microbial cell to release beta-
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galactosidase. Pasteurization is also thought to reduce lac-
tose auto-digestion capacity [27, 46–48].
Altering the microbial flora through consumption of
probiotic supplements is thought to support improved
lactose tolerance. Studies have yielded mixed results on
the efficacy of probiotics in improving breath test results
or improving abdominal symptoms [10, 20, 49, 50].
These mixed results may be related to variations in prep-
aration of the probiotic product. This study uses a unique
strain of Lactobacillus acidophilus known as DDS-1. This
unique strain of Lactobacillus acidophilus was discovered
by Dr. Khem Shahani at the University of Nebraska in
1959. A recent single-blind, crossover study of twelve sub-
jects revealed that Lactobacillus acidophilus DDS-1 per-
sisted in the gastrointestinal tract 1 day after consumption,
indicating that the strain survived gastric passage [43].
After an 8-day washout, however, the probiotic strains
were no longer detected. With the knowledge that DDS-1
Fig. 1 Attrition chart
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persists in the gut, we aimed to determine for the first time
in a randomized, double-blind, crossover design if the
DDS-1 strain was more effective than placebo in alleviat-
ing symptoms of lactose intolerance.
The results of this study suggest that although no signifi-
cant changes were observed for HBT, the DDS-1 strain of
Lactobacillus acidophilus can help improve gastrointestinal
symptoms of lactose intolerance such as diarrhea, abdom-
inal cramping, and vomiting. The lack of significant effects
on HBT further establishes that lactose malabsorption and
lactose intolerance carry some degree of mutual exclusivity
[49]. This is further demonstrated through a randomized
trial on subjects with self-reported lactose intolerance that
found ingestion of Lactobacillus acidophilus BG2FO4,
a strain with high lactase activity and strong intestinal
adherence as measured in an in vitro experiment,
twice a day for seven days did not significantly alter
overall hydrogen production compared to baseline
[49]. This study also did not find significant changes
in symptom scores. Based on this, the findings of our
study may suggest that changes in HBT occur after
improvement in symptoms.
Of note, subjects during visit 4 of the active phase were
still noted to have increased symptoms of flatulence after
4 weeks, which was not increased in the placebo group.
Many studies report improved flatulence after consump-
tion of probiotics [20, 51, 52], thus this may represent
spurious data related to insufficient statistical power.
Alternatively, it has been suggested that initial use of
Lactobacillus supplements may include abdominal dis-
comfort and increased flatulence while the probiotic bac-
teria colonizes in the intestinal tract [53]. Thus a longer
Table 4 Within-group analysis of placebo group-Week 4, Hour 0 to Hour 6
Time point n Mean Std. deviation Std. error mean p-value Percent change
Diarrhea Hour 0 24 0.42 .974 0.199 0.006 * 380.00 %
Hour 6 24 2.00 2.519 0.514
Abdominal cramping Hour 0 24 1.04 1.517 0.310 0.004 * 124.00 %
Hour 6 24 2.33 2.014 0.411
Vomiting Hour 0 24 0.21 0.415 0.085 1.000 80.00 %
Hour 6 24 0.38 0.970 0.198
Audible bowel sounds Hour 0 24 1.54 1.693 0.346 0.053 48.65 %
Hour 6 24 2.29 2.216 0.452
Flatulence Hour 0 24 1.58 1.840 0.376 0.167 71.05 %
Hour 6 24 2.71 2.545 0.519
Overall Hour 0 24 4.79 5.610 1.145 0.017 102.61 %
Hour 6 24 9.71 8.379 1.710
*statistically significant at p < 0.01
Table 5 Within-group analysis of active group - Week 4, Hour 0 to Hour 6
Time point n Mean Std. deviation Std. error mean p-value Percent change
Diarrhea Hour 0 22 0.45 1.595 0.340 0.289 190.00 %
Hour 6 22 1.32 2.255 0.481
Abdominal cramping Hour 0 22 .64 1.177 0.251 0.227 128.57 %
Hour 6 22 1.45 2.087 0.445
Vomiting Hour 0 22 0.05 0.213 0.045 1.000 0.00 %
Hour 6 22 0.05 0.213 0.045
Audible bowel sounds Hour 0 22 1.45 1.711 0.365 0.057 46.88 %
Hour 6 22 2.14 1.959 0.418
Flatulence Hour 0 23 1.30 1.743 0.364 0.004 ** 150.00 %
Hour 6 23 3.26 2.562 0.534
Overall Hour 0 22 3.86 5.167 1.102 0.027 * 112.94 %
Hour 6 22 8.23 7.502 1.599
*statistically significant at p < 0.05; ** statistically significant at p > 0.01
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duration study may be employed to better understand the
relationship between DDS-1 and flatulence.
This study provides preliminary evidence that the DDS-1
strain of Lactobacillus acidophilus not only persists in the
gastrointestinal tract after prolonged use, but also can pro-
vide symptom benefit compared with placebo among indi-
viduals who consume the product for a course of 4 weeks.
This study did not determine the number of patients with
actual lactose maldigestion. It is possible, therefore, that not
all patients who believe that they are lactose intolerant are
actual maldigesters. Future randomized, placebo-controlled
clinical trials are warranted to confirm the results of this
study and to further determine the efficacy of the DDS-1
strain on other therapeutic areas which lactobacillus
is postulated to affect, such as the immune system,
cholesterol levels, microbial infection, and cancer.
Limitations
A major limitation of this study is the limited time frame
of four weeks. While many studies have demonstrated
responses to probiotic consumption within this time
frame, extension of both active and placebo groups may
have demonstrated a more significant improvement in
the 0-h to 6-h symptom score after prolonged use. This
may be particularly true for the flatulence measurement,
which was found to significantly increase on lactose chal-
lenge after 4 weeks of probiotic use. Prior studies have
noted improvement in flatulence symptoms after probiotic
use [20, 51, 52]. Similarly, lack of significant change in
hydrogen breath testing may be related to insufficient time
for the probiotic bacteria to fully colonize, as seen in other
studies with treatment phases of 4 weeks or less [49, 54].
Another limitation of this study is the absence of stool
sample data demonstrating persistence of lactobacillus
strain in the stool. However, it has been previously
reported that the DDS-1 strain does successfully estab-
lish in the human gastrointestinal tract [43].
Conclusion
The present study has found that this unique DDS-1 strain
of Lactobacillus acidophilus, manufactured by Nebraska
Cultures, Inc., is safe to consume and improves abdominal
symptom scores with respect to diarrhea, cramping, and
vomiting during an acute lactose challenge.
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